NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Forecast, Price & News $19.43 +0.50 (+2.64%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$18.74▼$19.5850-Day Range$16.69▼$28.5852-Week Range$8.80▼$34.13Volume460,464 shsAverage Volume506,562 shsMarket Capitalization$566.58 millionP/E RatioN/ADividend YieldN/APrice Target$50.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability BioXcel Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside158.8% Upside$50.29 Price TargetShort InterestHealthy16.69% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews Sentiment0.43Based on 3 Articles This WeekInsider TradingSelling Shares$2.08 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.87) to ($5.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector177th out of 986 stocksPharmaceutical Preparations Industry73rd out of 478 stocks 3.4 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.29, BioXcel Therapeutics has a forecasted upside of 158.8% from its current price of $19.43.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.69% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 5.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 1.9 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BioXcel Therapeutics this week, compared to 3 articles on an average week.Search Interest16 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,083,524.00 in company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.35% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($6.87) to ($5.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioXcel Therapeutics (NASDAQ:BTAI) StockBioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. It also focuses on utilizing cutting-edge technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.Read More Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Stock News HeadlinesJune 2, 2023 | finance.yahoo.comBTAI: Promising Results for Part 1 of SERENITY III Trial…May 30, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $50.29 Consensus PT from BrokeragesJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 28, 2023 | seekingalpha.comBioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 WillMay 27, 2023 | americanbankingnews.comInsider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells $167,635.00 in StockMay 27, 2023 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Stock Price Down 10.8% on Insider SellingMay 26, 2023 | markets.businessinsider.comGoldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To KnowMay 26, 2023 | msn.comGoldman Sachs Maintains BioXcel Therapeutics (BTAI) Neutral RecommendationJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 26, 2023 | markets.businessinsider.comWhere BioXcel Therapeutics Stands With AnalystsMay 26, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Bioxcel Therapeutics (BTAI)May 25, 2023 | finance.yahoo.comBioXcel Stock Crashes 25% As Bid To Double Its Market Appears Less CertainMay 25, 2023 | msn.comWhy Shares of BioXcel Therapeutics Are Dropping ThursdayMay 25, 2023 | finance.yahoo.comBioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaMay 22, 2023 | msn.comLooking Into BioXcel Therapeutics's Return On Capital EmployedMay 22, 2023 | seekingalpha.comBioXcel Therapeutics: Clinical Trial Milestones Drive Stock But Slow Market Adoption PersistsMay 19, 2023 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Shares Down 3.4% After Insider SellingMay 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Medios AG (OtherMEDOF)May 17, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Insider Javier Rodriguez Sells 1,785 SharesMay 17, 2023 | americanbankingnews.comRichard I. Steinhart Sells 5,000 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) StockMay 17, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Issued By HC WainwrightMay 16, 2023 | msn.comBioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression TreatmentMay 16, 2023 | finance.yahoo.comBioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) ProgramMay 16, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Significant Decline in Short InterestMay 16, 2023 | americanbankingnews.comZacks Small Cap Comments on BioXcel Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:BTAI)May 12, 2023 | msn.comMizuho Maintains BioXcel Therapeutics (BTAI) Buy RecommendationMay 11, 2023 | seekingalpha.comBioXcel Therapeutics: It Is All About Key Upcoming Clinical Data ReadoutsSee More Headlines BTAI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Company Calendar Last Earnings5/08/2023Today6/05/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees89Year Founded2017Price Target and Rating Average Stock Price Forecast$50.29 High Stock Price Forecast$76.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+162.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,760,000.00 Net MarginsN/A Pretax Margin-32,199.83% Return on Equity-177.74% Return on Assets-85.13% Debt Debt-to-Equity Ratio1.79 Current Ratio6.16 Quick Ratio6.10 Sales & Book Value Annual Sales$380,000.00 Price / Sales1,471.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book7.00Miscellaneous Outstanding Shares29,160,000Free Float18,721,000Market Cap$559.29 million OptionableNot Optionable Beta1.09 Social Links Key ExecutivesVimal D. MehtaPresident, Chief Executive Officer & DirectorRichard I. SteinhartChief Financial & Accounting Officer, Senior VPFrank D. YoccaChief Scientific Officer & Senior Vice PresidentVincent J. O'NeillChief Medical Officer & Senior Vice PresidentJavier RodriguezSecretary, Chief Legal Officer & Senior VPKey CompetitorsGH ResearchNASDAQ:GHRSLexicon PharmaceuticalsNASDAQ:LXRXAldeyra TherapeuticsNASDAQ:ALDXPhibro Animal HealthNASDAQ:PAHCAclaris TherapeuticsNASDAQ:ACRSView All CompetitorsInsiders & InstitutionsVimal MehtaSold 6,500 sharesTotal: $167,635.00 ($25.79/share)JPMorgan Chase & Co.Bought 5,696 shares on 5/18/2023Ownership: 0.059%New York State Common Retirement FundSold 686 shares on 5/18/2023Ownership: 0.037%State Street CorpBought 1,392,114 shares on 5/16/2023Ownership: 6.038%Geode Capital Management LLCBought 8,130 shares on 5/16/2023Ownership: 1.314%View All Insider TransactionsView All Institutional Transactions BTAI Stock - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price forecast for 2023? 7 equities research analysts have issued 12-month price objectives for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $22.00 to $76.00. On average, they anticipate the company's stock price to reach $50.29 in the next year. This suggests a possible upside of 162.2% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2023? BioXcel Therapeutics' stock was trading at $21.48 on January 1st, 2023. Since then, BTAI shares have decreased by 10.7% and is now trading at $19.18. View the best growth stocks for 2023 here. Are investors shorting BioXcel Therapeutics? BioXcel Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,350,000 shares, a drop of 5.4% from the April 30th total of 3,540,000 shares. Based on an average trading volume of 518,100 shares, the short-interest ratio is currently 6.5 days. Approximately 16.7% of the company's stock are short sold. View BioXcel Therapeutics' Short Interest. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Monday, May, 8th. The company reported ($1.84) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by $0.28. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.50 million. During the same period in the prior year, the business posted ($1.12) earnings per share. What ETFs hold BioXcel Therapeutics' stock? ETFs with the largest weight of BioXcel Therapeutics (NASDAQ:BTAI) stock in their portfolio include WisdomTree Artificial Intelligence and Innovation Fund (WTAI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is BioXcel Therapeutics' stock symbol? BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI." Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.74%), State Street Corp (6.04%), BlackRock Inc. (4.72%), Wellington Management Group LLP (4.60%), Artemis Investment Management LLP (3.38%) and Geode Capital Management LLC (1.31%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioXcel Therapeutics' stock price today? One share of BTAI stock can currently be purchased for approximately $19.18. How much money does BioXcel Therapeutics make? BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $559.29 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($6.63) on an earnings per share basis. How can I contact BioXcel Therapeutics? BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com. This page (NASDAQ:BTAI) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.